Vertex Pharmaceuticals (VRTX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near ...

Erste Group upgraded Vertex Pharmaceuticals (VRTX) to Buy from Hold. The firm expects the company to “develop positively in the coming quarters ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Alphatec Holdings (ATEC – Research Report), Vertex ...

Vertex Pharmaceuticals VRTX has outperformed the market over the past 15 years by 5.86% on an annualized basis producing an average annual return of 17.7%. Currently, Vertex Pharmaceuticals has a ...

Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) will be reporting results tomorrow afternoon. Here’s what to look for. Vertex Pharmaceuticals beat analysts’ revenue expectations by 3.2% last ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

In this article, we are going to take a look at where Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) stands against other Renaissance Technologies portfolio's top stock picks. The American ...

Vertex Pharmaceuticals stock (NASDAQ: VRTX) is trending higher after the U.S. FDA approved Journavx – an oral non-opioid pain medication. This is a big win for Vertex, given that Journavx can ...

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF ...

Cantor Fitzgerald issued their FY2025 EPS estimates for shares of Vertex Pharmaceuticals in a research note issued to ...

Vertex Pharmaceuticals (NASDAQ:VRTX – Free Report) had its price target upped by Royal Bank of Canada from $407.00 to $408.00 ...